Source-grounded facts extracted from Zivo Bioscience, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Zivo Bioscience, Inc. incurred convertible notes of $250,000 with an accredited investor at 10% interest per annum maturing two years after the date of issuance.
“On July 8, 2025, Zivo Bioscience, Inc. (the“Company”) issued a Bridge Promissory Note in the principal amount of $250,000 and accompanying warrant to purchase 1,793 shares”
Laith Yaldoo was appointed as Director at Zivo Bioscience, Inc..
“On July 11, 2024, the Board of Directors of ZIVO Bioscience Inc., (the “Company”) increased its size from four (4) to five (5) members and appointed Laith Yaldoo to fill the vacancy.”
Zivo Bioscience, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 22, 2023, the Company was notified by The Nasdaq Stock Market LLC (“ Nasdaq ”) that as a result of the Company’s previously disclosed noncompliance with Nasdaq Listing Rule 5550(b)(1), Nasdaq has determined to delist the Company’s common stock from the Nasdaq Capital Market and, accordingly, will suspend trading in the Company’s common stock effective at the open of business, on November 27, 2023. Nasdaq further indicated that it will file a Form 25 Notification of Delisting with the Securities and Exchange Commission (the “ SEC ”). The Company has applied to have its common stock quo”
Zivo Bioscience, Inc. entered into Subscription Agreement with HEP Investments, LLC valued at $150,000 (effective 2023-11-16).
“On November 16, 2023, Zivo Bioscience, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) with the HEP Investments, LLC, a significant shareholder of the Company, (the “ Subscriber ”), pursuant to which the Company, in a private placement (the “ Private Placement ”), agreed to issue and sell to the Subscriber a 10% promissory note with a principal amount of $150,000 (the “ Note ”).”
Zivo Bioscience, Inc.: Amended articles to effect a 1-for-6 reverse stock split and reduce authorized common shares from 150,000,000 to 25,000,000 (effective 2023-10-26).
“On October 24, 2023, Zivo Bioscience, Inc. (the “Company”) filed a certificate of amendment to its articles of incorporation with the Secretary of State of the State of Nevada (the “Certificate of Amendment”) to (i) effectuate a reverse stock split (the “Reverse Stock Split”) of its issued and outstanding shares of common stock and treasury shares on a 1-for-6 basis and (ii) decrease the number of total authorized shares of Common Stock of the Company from 150,000,000 to 25,000,000 shares.”
Zivo Bioscience, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).
“August 4, 2023, the Company received a notification letter from the Nasdaq notifying the Company that the Panel has granted the Company’s request to provide an extension until November 20, 2023 (the “Exception Period”), to regain compliance with the Stockholders’ Equity Rule for continued listing on Nasdaq. The Panel further noted that the Exception Period for continued listing is subject to a filing of a registration statement on Form S-1 by the Company with the U.S. Securities and Exchange Commission (the “SEC”) on or before October 5, 2023. The Panel concluded that the Exception Period is”
Zivo Bioscience, Inc. entered into Placement Agent Agreement with Maxim Group LLC valued at 7.0% of the gross proceeds (effective 2023-06-30).
“On June 30, 2023, the Company entered into a placement agency agreement (the “Placement Agent Agreement”) with Maxim Group LLC (the “Placement Agent”) pursuant to which the Company engaged Maxim as the placement agent in connection with the Offerings.”
Zivo Bioscience, Inc. entered into Securities Purchase Agreement with a single institutional investor valued at aggregate gross proceeds from the Registered Offering of approximately $4.0 million (effective 2023-06-30).
“On June 30, 2023, Zivo Biosciences, Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor named therein (the “Investor”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investor (the “Registered Offering”), (i) an aggregate of 1,030,000 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (“Common Stock”), at an offering price of $2.67 per share and (ii) an aggregate of 468,130 pre-funded warrants exercisable for shares of Common Stock (the “Pre-Funded Warrants”) at an offering price of $2.6699 per Pre-Funded Warrant, for aggregate gross proceeds from the Registered Offering of approximately $4.0 million before deducting the Placement Agent’s fee and related offering expenses.”
Zivo Bioscience, Inc. shareholders approved Approval (on an advisory basis) of the compensation of the Company's named executive officers at the 2023-06-12 meeting.
“Proposal 3 — Approval (on an advisory basis) of the compensation of the Company's named executive officers Votes For Votes Against Votes Abstain 3,252,348 186,946 4,056”
Zivo Bioscience, Inc. shareholders approved Ratification of the appointment of BDO USA, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-12 meeting.
“Proposal 2—Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Votes Abstain 5,982,232 164,958 579”
Zivo Bioscience, Inc. shareholders approved Election of one director to serve a three-year term until the 2026 annual meeting of stockholders at the 2023-06-12 meeting.
“Proposal 1—Election of Directors Nominee Votes For Votes Withheld Broker Non-Votes Christopher D. Maggiore 3,050,053 393,297 2,704,419”
Zivo Bioscience, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)).
“May 23, 2023, Zivo Biosciences, Inc. (the “Company”) was notified by the Listing Qualifications department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the Company’s non-compliance with the $2.5 million stockholders’ equity requirement for continued listing on The Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b) (the “Rule”), as of May 22, 2023, the Company’s common stock was subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company plans to timely request a hearing bef”
Zivo Bioscience, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 22, 2022, Zivo Bioscience, Inc. (the “Company”) received written notice from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders' equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, has fallen below $2.5 million. The notice also indicates that the Company does not meet the alternative compliance standards. Under applicabl”
Andrew Dahl was terminated as Chief Executive Officer and President at Zivo Bioscience, Inc..
“The Company reaffirms that the Board terminated Dahl for cause.”
Andrew A. Dahl resigned as member of the board of directors at Zivo Bioscience, Inc..
“on February 18, 2022, Mr. Dahl resigned from his position as a member of the Company’s board of directors.”
Andrew A. Dahl was terminated as President and Chief Executive Officer at Zivo Bioscience, Inc..
“the Company terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.”
John B. Payne was appointed as President and Chief Executive Officer at Zivo Bioscience, Inc..
“Effective as of January 7, 2022, the Board of the Company appointed Mr. John B. Payne as the Company’s President and Chief Executive Officer.”
Andrew A. Dahl was terminated as President and Chief Executive Officer at Zivo Bioscience, Inc..
“On January 4, 2022, Zivo Bioscience, Inc. (the “Company” ) terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.”
Rondeau resigned as Director at Zivo Bioscience, Inc..
“On September 16, 2021, Mr. Rondeau gave notice of his intent to resign from the Board of Directors (the “Board”) of Zivo Bioscience, Inc. (the “Company”) effective on September 17, 2021.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.